EYEPOINT INC
EYPTNASDAQTrading Snapshot
- Day Range
- $0.23 β $0.27
- 52-Week Range
- $0.23 β $19.11
- Volume (shares)
- 4,938,937
- Avg Volume (shares)
- β
- Shares Outstanding
- 86.2M
- Next Earnings
- 2027-03-02
Fundamentals Snapshot
- Annual Revenue
- $31M
- Last Q Revenue
- $756,000
- P/E Ratio
- β
- P/S Ratio
- 9.6x
- EPS (TTM)
- $-3.74
- Dividend Yield
- β
- Dilution (1yr)
- +28.6%
EYEPOINT INC
EYPTAbout EYEPOINT INC
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against EyePoint, Inc. (NASDAQ: EYPT) -- Investors Who Suffered Losses Are Encouraged to Contact the Firm.
Lead Plaintiff Deadline: January 19, 2027. Investors who purchased (NASDAQ: EYPT) securities between March 27, 2025 and August 14, 2026 may be eligible to recover losses.

EYPT INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds EyePoint (EYPT) Investors of Securities Class Action Lawsuit Deadline on January 19, 2027
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In EyePoint To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in EyeP

Kaplan Fox & Kilsheimer LLP Alerts EyePoint, Inc. (EYPT) Investors to a Securities Class Action Deadline on January 19, 2027
New York, New York--(Newsfile Corp. - November 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT) on behalf of

EYPT DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds EyePoint (EYPT) Investors of Securities Class Action Lawsuit Deadline on January 19, 2027
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In EyePoint To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in EyeP

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages EyePoint, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Lawsuit - EYPT
New York, New York--(Newsfile Corp. - November 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of EyePoint, Inc. (NASDAQ: EYPT) b

EyePoint, Inc.Β (NASDAQ:Β EYPT) SHAREHOLDER ALERT: InvestorsΒ WithΒ Losses May Seek to Lead the Class Action inΒ EyePoint, Inc.Β Securities Lawsuit β Contact Portnoy Law Firm
LOS ANGELES, Nov. 20, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies investors in EyePoint, Inc. (NASDAQ: EYPT) that a securities class action lawsuit has been filed on behalf of shareholders who purchased or oth